Secondary Acute Myeloid Leukemia — Trials

Secondary Acute Myeloid Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

212 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 46
Recruiting: 21
Ph III recruiting: 0
Growth YoY: —
Industry share: 7%
Top sponsor: National Cancer Institute (NCI)
Termination share: 31.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (39)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00715637	Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study	unknown	Phase 3	420	Antisoma ResearchINDUSTRY	23	Oct 13, 2010	clinicaltrials
NCT00209833	Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T	unknown	Phase 2 / Phase 3	200	Hannover Medical SchoolOTHER	1	Nov 18, 2005